Synonyms: Margenza® | margetuximab-cmkb | MGAH-22
margetuximab is an approved drug (FDA (2020))
Compound class:
Antibody
Comment: Margetuximab is a chimeric monoclonal antibody targeting epidermal growth factor receptor 2 (ERBB2).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence search of patented sequences reveals a 100% match between the heavy chain variable domain of margetuximab and SEQ ID NO: 13 from patent US8802093 B2, and antibody clone ch4D5-FcMT3 [2]. Although the patent describes performing Biacore assays to determine antibody-target (ERBB2) affinity, a KD value is not provided. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|